期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
C-X-C chemokine receptor type 5+CD8+T cells as immune regulators in hepatitis Be antigen-positive chronic hepatitis B under interferonalpha treatment
1
作者 Zhen-Yu Xu zhong-shang dai +1 位作者 Guo-Zhong Gong Min Zhang 《World Journal of Gastroenterology》 SCIE CAS 2025年第3期73-83,共11页
BACKGROUND C-X-C chemokine receptor type 5(CXCR5)+CD8+T cells represent a unique immune subset with dual roles,functioning as cytotoxic cells in persistent viral infections while promoting B cell responses.Despite the... BACKGROUND C-X-C chemokine receptor type 5(CXCR5)+CD8+T cells represent a unique immune subset with dual roles,functioning as cytotoxic cells in persistent viral infections while promoting B cell responses.Despite their importance,the specific role of CXCR5+CD8+T cells in chronic hepatitis B(CHB),particularly during interferon-alpha(IFN-α)treatment,is not fully understood.This study aims to elucidate the relationship between CXCR5+CD8+T cells and sustained serologic response(SR)in patients undergoing 48 weeks of pegylated IFN-α(peg-IFN-α)treatment for CHB.AIM To elucidate the relationship between CXCR5+CD8+T cells and sustained SR in patients undergoing 48 weeks of peg-IFN-αtreatment for CHB.METHODS This study enrolled 60 patients with hepatitis Be antigen(HBeAg)-positive CHB undergoing 48 weeks of peg-IFN-αtreatment.Participants were assessed for eligibility based on criteria such as persistent HBsAg-positive status for at least six months,HBeAb-negative,hepatitis B virus DNA levels exceeding 2×104 copies/mL,and alanine aminotransferase(ALT)levels between 2 and 10 times the upper limit of normal.Blood samples were collected at baseline and at weeks 12,24,48,and a 24-week treatment-free follow-up(week 72)to measure serum interleukin(IL)-21 concentration via ELISA and to analyze CXCR5 and programmed death-ligand 1(PD-L1)expression on CD8+T cells by flow cytometry,CXCR5 is a chemokine receptor that directs immune cells to specific tissues,while PD-L1 is a protein that regulates immune responses by inhibiting T cell activity.RESULTS Patients with CHB exhibited significantly lower levels of circulating CXCR5+CD8+T cells compared to healthy controls(P<0.01).Notably,CXCR5+CD8+T cells were prominently expressed in patients who achieved sustained SR compared to non-SR(NSR).A significant correlation was observed between CXCR5 and PD-L1 expression(r=-0.189,P=0.002).However,there was no significant correlation between serum IL-21 levels and CXCR5+CD8+lymphocytes(r=-0.03,P=0.625)or serum ALT levels(r=0.026,P=0.678).CONCLUSION The enhanced expression of CXCR5+CD8+T cells in patients achieving HBeAg seroconversion during IFN-αtreatment suggests that these cells play a crucial role in antiviral immune responses against hepatitis B.This study highlights the potential of CXCR5+CD8+T cells as immune regulators in CHB,which may inform future therapeutic strategies to optimize antiviral treatments. 展开更多
关键词 C-X-C chemokine receptor type 5 Programmed death-ligand 1 Interleukin-21 Pegylated interferon-alpha Chronic hepatitis B
下载PDF
Changes in Global Initiative for Chronic Obstructive Lung Disease ABCD Groups and the Impact of Regrouping on Treatment: A Comparison of 2017 and 2014 被引量:2
2
作者 Ya-Nan Cui Ping Chen +1 位作者 zhong-shang dai Yan Chen 《Chinese Medical Journal》 SCIE CAS CSCD 2018年第9期1113-1114,共2页
To the Editor:In 2017,the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a total revised document (GOLD 2017),[1] in which one important change is the "ABCD"classification for the manage... To the Editor:In 2017,the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a total revised document (GOLD 2017),[1] in which one important change is the "ABCD"classification for the management of patients with chronic obstructive pulmonary disease (COPD).The assessment tool of the GOLD 2011 combined the symptomatic assessment with the patient's spirometric classification and/or risk of exacerbations,and the revised GOLD 2014[2] added the history of hospitalization due to an exacerbation in the preceding year as a method of assessing exacerbation risk.However,increasing evidence suggested the limitations of the forced expiratory volume in 1 s (FEV1) in influencing prognostic and therapeutic decisions.The new GOLD 2017 classification separates spirometric grades from the "ABCD"groups.[1] To date,the impact of this revision on grouping and subsequent drug selection has been insufficiently studied. 展开更多
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部